Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.64 |
| ▸ | MMP2 | P08253 | 4/20 | 0.64 |
| ▸ | MMP9 | P14780 | 4/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.49 |
| ▸ | TUBB | P07437 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679758 | 0.84 | HDAC3 (0.46) | MMP1MMP2MMP9EGFRNPC1 | |
| SCHEMBL2679766 | 0.84 | HDAC3 (0.46) | MMP1MMP2MMP9EGFRNPC1 | |
| SCHEMBL13320651 | 0.81 | TRPM2 (0.60) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL9767884 | 0.81 | TRPM2 (0.60) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL2679660 | 0.80 | ALDH1A1 (0.54) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL2679665 | 0.80 | ALDH1A1 (0.54) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL6582938 | 0.80 | NPC1 (0.51) | MMP1MMP2MMP9EGFRNPC1 | |
| SCHEMBL6582936 | 0.80 | NPC1 (0.51) | MMP1MMP2MMP9EGFRNPC1 | |
| SCHEMBL13352237 | 0.79 | MMP1 (0.78) | MMP1MMP2MMP9EGFRNPC1 | |
| N-O-Tolylcinnamamide SCHEMBL2593756 | 0.78 | MMP1 (1.00) | MMP1MMP2MMP9EGFRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130497-A1 | Therapeutic Compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130497-A1 | Therapeutic Compounds | NFATC1, NAT1, AADAC | MMP1 19/4885MMP2 88/4885MMP9 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.